Custom-Built Molecule May Improve On Its Natural Counterpart
Monday, February 22, 2021
Ten years ago, a young woman from Chicago came to the National Institutes of Health with a rare genetic condition. A mutation in her DNA was making her metabolic system malfunction, causing levels of fat molecules called triglycerides in her blood to skyrocket far out of the normal range. This triggered inflammation in her pancreas, a painful and potentially life-threatening condition known as pancreatitis. She couldn’t understand why there wasn’t any kind of treatment to help her.
IRP senior investigator Alan T. Remaley, M.D., Ph.D., took on the challenge with the help of Anna Wolska, Ph.D., a research fellow in his lab. Dr. Remaley leads the Lipoprotein Metabolism Section in the National Heart, Lung, and Blood Institute (NHLBI), where he and Dr. Wolska study lipoproteins, small particles that transport fats such as cholesterol and triglycerides through the bloodstream to be broken down and used by cells for energy. Their efforts to help that young woman ultimately led to the discovery — published last January — of a new strategy for reducing triglycerides in order to treat serious ailments like pancreatitis and heart disease.
Alteration Helps Prospective Drug Persist Longer in Rodents’ Bodies
Tuesday, February 4, 2020
Even the best construction crew cannot repair a building if it is called away from the site before it can begin its work. Similarly, while the body’s ability to cleanse itself of chemicals can prevent the buildup of toxins, it can also stymie the therapeutic effects of medications. IRP researchers recently found that modifying a prospective treatment for heart failure to help it persist longer in the body boosted its beneficial effects in mice.
Five Questions with Dr. Nehal Mehta
Thursday, August 29, 2019
Most Americans know someone who has been affected by heart disease. Despite its status as the leading cause of death in the U.S. today, rates of heart disease have actually been steadily falling since they hit their peak in 1968. In fact, between 1970 and 2005, the life expectancy of the average American increased over 70 percent due in part to reductions in heart disease-related deaths.
Research conducted by IRP scientists has played a key role in curbing the heart disease epidemic by helping identify now well-known risk factors for heart disease, such as high blood pressure, obesity, and physical inactivity. However, not all risk factors are so commonly known. A 2017 study by IRP Lasker Clinical Research Scholar Nehal Mehta, M.D., M.S.C.E., revealed that untreated psoriasis — a chronic, relapsing, inflammatory skin disease — is linked to an elevated risk for premature coronary artery disease. Dr. Mehta’s research demonstrated a strong link between psoriasis-induced skin inflammation and and inflammation of the blood vessels, a precursor to heart disease. Through this study, the largest ongoing study of individuals with psoriasis to-date, Dr. Mehta’s team has concluded that controlling psoriasis-associated skin disease could be an important means of reducing cardiac risk in this population.
Tuesday, June 14, 2016
Hi, my name is James. I’ve always really liked science and I want to be a scientist when I grow up, but I never got to see where scientists work until I went to Take Your Child to Work Day at NIH with my Auntie Kit. It was awesome!
Friday, May 1, 2015
This dapper bee from 1977 advertised an NHLBI-sponsored multicenter, randomized, double-blind, and placebo-controlled trial designed to test the benefits of beta-blockers for people who had had a heart attack. The study was called the Beta-Blocker Heart Attack Trial (BHAT). Ah, you say—that’s why the bee in the hat!